JP7465881B2 - フロセミドの濃縮液体医薬製剤及びそれを投与する方法 - Google Patents

フロセミドの濃縮液体医薬製剤及びそれを投与する方法 Download PDF

Info

Publication number
JP7465881B2
JP7465881B2 JP2021542438A JP2021542438A JP7465881B2 JP 7465881 B2 JP7465881 B2 JP 7465881B2 JP 2021542438 A JP2021542438 A JP 2021542438A JP 2021542438 A JP2021542438 A JP 2021542438A JP 7465881 B2 JP7465881 B2 JP 7465881B2
Authority
JP
Japan
Prior art keywords
liquid pharmaceutical
pharmaceutical formulation
pharma
ceutically acceptable
furosemide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021542438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518900A5 (https=
JP2022518900A (ja
Inventor
グロッシ，アルフレード
コストラバ，ブリット
オー．ルカ オグンレイエ，オラントクンボ
テリー，シャノン
コペンハーゲン，フランシスカス
Original Assignee
エスシーファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスシーファーマシューティカルズ インコーポレイテッド filed Critical エスシーファーマシューティカルズ インコーポレイテッド
Publication of JP2022518900A publication Critical patent/JP2022518900A/ja
Publication of JP2022518900A5 publication Critical patent/JP2022518900A5/ja
Priority to JP2024059099A priority Critical patent/JP7738696B2/ja
Application granted granted Critical
Publication of JP7465881B2 publication Critical patent/JP7465881B2/ja
Priority to JP2025145578A priority patent/JP2025170052A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
JP2021542438A 2019-01-31 2020-01-30 フロセミドの濃縮液体医薬製剤及びそれを投与する方法 Active JP7465881B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024059099A JP7738696B2 (ja) 2019-01-31 2024-04-01 フロセミドの濃縮液体医薬製剤及びそれを投与する方法
JP2025145578A JP2025170052A (ja) 2019-01-31 2025-09-02 フロセミドの濃縮液体医薬製剤及びそれを投与する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962799215P 2019-01-31 2019-01-31
US62/799,215 2019-01-31
PCT/US2020/015799 WO2020160210A1 (en) 2019-01-31 2020-01-30 Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024059099A Division JP7738696B2 (ja) 2019-01-31 2024-04-01 フロセミドの濃縮液体医薬製剤及びそれを投与する方法

Publications (3)

Publication Number Publication Date
JP2022518900A JP2022518900A (ja) 2022-03-17
JP2022518900A5 JP2022518900A5 (https=) 2023-01-31
JP7465881B2 true JP7465881B2 (ja) 2024-04-11

Family

ID=69740677

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021542438A Active JP7465881B2 (ja) 2019-01-31 2020-01-30 フロセミドの濃縮液体医薬製剤及びそれを投与する方法
JP2024059099A Active JP7738696B2 (ja) 2019-01-31 2024-04-01 フロセミドの濃縮液体医薬製剤及びそれを投与する方法
JP2025145578A Pending JP2025170052A (ja) 2019-01-31 2025-09-02 フロセミドの濃縮液体医薬製剤及びそれを投与する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024059099A Active JP7738696B2 (ja) 2019-01-31 2024-04-01 フロセミドの濃縮液体医薬製剤及びそれを投与する方法
JP2025145578A Pending JP2025170052A (ja) 2019-01-31 2025-09-02 フロセミドの濃縮液体医薬製剤及びそれを投与する方法

Country Status (15)

Country Link
US (10) US11998555B2 (https=)
EP (1) EP3917495A1 (https=)
JP (3) JP7465881B2 (https=)
KR (2) KR102923666B1 (https=)
CN (2) CN118319852A (https=)
AU (2) AU2020214314B2 (https=)
BR (1) BR112021014637A2 (https=)
CA (1) CA3128033A1 (https=)
EA (1) EA202192129A1 (https=)
IL (2) IL285073B2 (https=)
MA (1) MA54865A (https=)
MX (2) MX2021009084A (https=)
PH (1) PH12021551811A1 (https=)
SG (1) SG11202108280RA (https=)
WO (1) WO2020160210A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2024512650A (ja) * 2021-04-02 2024-03-19 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下注入
EP4648761A1 (en) * 2023-01-09 2025-11-19 scPharmaceuticals Inc. Methods of treatment using loop diuretics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103371967A (zh) 2012-04-17 2013-10-30 上海禾丰制药有限公司 呋塞米注射液及其制剂工艺
JP2015516441A (ja) 2012-05-18 2015-06-11 ルオダ ファーマ ピーティーワイ リミテッド 液体配合剤
JP2016515623A (ja) 2013-04-05 2016-05-30 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下投与用の医薬製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2134671A1 (de) 1971-07-08 1973-01-25 Josef Dipl Chem Dr Rer N Klosa Pharmazeutische praeparate
US4663348A (en) 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
US4853439A (en) 1987-10-09 1989-08-01 Gaf Corporation Water-soluble complexes of water-insoluble organic compounds
EP0416232B1 (en) * 1989-08-21 1995-08-16 American Cyanamid Company Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
WO1992021769A1 (en) 1991-05-30 1992-12-10 Abbott Laboratories Reagents containing a nonspecific binding blocker in ion-capture binding assays
US5633240A (en) 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ATE409280T1 (de) 2005-12-28 2008-10-15 Sensile Pat Ag Mikropumpe
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
EP2334302B1 (en) 2008-09-09 2018-03-21 Cima Labs Inc DOSAGE FORMS FOR ACTIVE INGREDIENTS THAT ARE LOWLY IONIZABLE
US20110060280A1 (en) 2009-09-04 2011-03-10 Sean Caffey Adhesive skin patch with pump for subcutaneous drug delivery
AU2012325801B2 (en) 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103371967A (zh) 2012-04-17 2013-10-30 上海禾丰制药有限公司 呋塞米注射液及其制剂工艺
JP2015516441A (ja) 2012-05-18 2015-06-11 ルオダ ファーマ ピーティーワイ リミテッド 液体配合剤
JP2016515623A (ja) 2013-04-05 2016-05-30 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下投与用の医薬製剤

Also Published As

Publication number Publication date
IL323325A (en) 2025-11-01
US20240299419A1 (en) 2024-09-12
JP2025170052A (ja) 2025-11-14
US20220096500A1 (en) 2022-03-31
KR20210150360A (ko) 2021-12-10
US20220168323A1 (en) 2022-06-02
US20240316071A1 (en) 2024-09-26
CN118319852A (zh) 2024-07-12
CN113747881A (zh) 2021-12-03
US11998555B2 (en) 2024-06-04
US12491193B2 (en) 2025-12-09
MX2021009084A (es) 2021-10-26
US12491194B2 (en) 2025-12-09
IL285073B1 (en) 2025-10-01
IL285073A (en) 2021-09-30
US11559535B2 (en) 2023-01-24
JP2024086756A (ja) 2024-06-28
MX2023012741A (es) 2024-02-27
KR102923666B1 (ko) 2026-02-06
AU2020214314B2 (en) 2025-09-18
BR112021014637A2 (pt) 2021-09-21
US20230277558A1 (en) 2023-09-07
EA202192129A1 (ru) 2021-10-19
AU2025283539A1 (en) 2026-01-15
WO2020160210A1 (en) 2020-08-06
JP7738696B2 (ja) 2025-09-12
IL285073B2 (en) 2026-02-01
CN113747881B (zh) 2024-05-14
US20220378806A1 (en) 2022-12-01
US20240325411A1 (en) 2024-10-03
US20220378805A1 (en) 2022-12-01
SG11202108280RA (en) 2021-08-30
KR20260036554A (ko) 2026-03-17
PH12021551811A1 (en) 2022-03-21
US12491195B2 (en) 2025-12-09
CA3128033A1 (en) 2020-08-06
US12048709B2 (en) 2024-07-30
US11497755B2 (en) 2022-11-15
JP2022518900A (ja) 2022-03-17
US11571434B2 (en) 2023-02-07
US20240307417A1 (en) 2024-09-19
EP3917495A1 (en) 2021-12-08
US12491196B2 (en) 2025-12-09
US20240316070A1 (en) 2024-09-26
US12491197B2 (en) 2025-12-09
AU2020214314A1 (en) 2021-08-19
MA54865A (fr) 2022-05-04

Similar Documents

Publication Publication Date Title
JP7738696B2 (ja) フロセミドの濃縮液体医薬製剤及びそれを投与する方法
JP7844438B2 (ja) フロセミドを使用した治療方法
KR20250099120A (ko) 루프 이뇨제의 액상 약학적 제형 및 이의 투여 방법
EA046008B1 (ru) Концентрированные жидкие фармацевтические составы фуросемида и способы их введения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240401

R150 Certificate of patent or registration of utility model

Ref document number: 7465881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150